| View |
|
BR-1059
|
Somatropin
|
Scitropin A
|
5 mg/ 1.5 mL (15IU)
|
Solution S.C. for Injection
|
Anterior Pituitary Lobe Hormone and Analogue
|
SANDOZ GmbH
|
Austria
|
Renewal
|
01 November 2023
|
27 November 2028
|
| View |
|
BR-1068
|
Trastuzumab
|
Herceptin
|
150 mg
|
Lyophilized Powder For Concentrate Solution For Infusion (IV)
|
-
|
Genentech, Inc.
|
United States of America
|
Initial (Variation)
|
11 October 2022
|
11 October 2027
|
| View |
BR-1072_PI_01.pdf
|
BR-1072
|
Ranibizumab
|
Lucentis
|
10 mg/mL
|
Solution For Injection (Intravitreal)
|
Antineovascular agents
|
Novartis Pharma Stein AG
|
Switzerland
|
Renewal
|
31 May 2024
|
29 May 2029
|
| View |
|
BR-1073
|
Filgrastim
|
Neubicyte
|
150 mcg/mL
|
Solution for Injection/ 150mg/ml
|
Hematopoietic Growth Factor
|
Harbin Pharmaceutical Group Bioengineering Co., Ltd.
|
China
|
Renewal
|
20 June 2022
|
26 May 2027
|
| View |
BR-1084_PI_01.pdf
|
BR-1084
|
Quadrivalent Seasonal Influenza Vaccine (Split)
Virion, Inactivated) 2024 Southern Hemisphere Strain.
|
Fluquadri
|
Formulation:
Each dose (0.5 mL) contains the following influenza strains*:
A/Victoria/4897/2022 (H1N1) pdm09-like strain
15 μg of HA**
(A/Victoria/4897/2022, IVR-238)
A/Thailand/8/2022 (H3N2)-like strain
15 μg of HA**
(A/California/122/2022, SAN-022)
B/Austria/1359417/2021-like strain
15 μg of HA**
(B/Michigan/01/2021, wild type)
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus
15 μg of HA**
(B/Phuket/3073/2013, wild type)
*Propagated in embryonated chicken eggs
|
Suspension for Injection (IM)
|
Vaccines
|
Sanofi Pasteur
|
U.S.A
|
Monitored Release (Strain Clearance)
|
05 April 2024
|
05 April 2025
|
| View |
|
BR-1091
|
Epoetin beta
|
Recormon
|
2,000 I.U./0.3mL
|
Solution for Injection (S.C./I.V.)
|
Antianemic Preparations
|
Roche Diagnostic GmbH
|
Germany
|
Renewal
|
18 September 2021
|
05 November 2026
|
| View |
|
BR-1093
|
Alteplase
|
Actilyse
|
50 mg
|
Powder for Solution for Infusion (IV
|
-
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
Initial (Variation)
|
19 September 2022
|
19 September 2027
|
| View |
BR-1101_PI_01.pdf
|
BR-1101
|
Tocilizumab
|
Actemra
|
162 mg/ 0.9 mL
|
Solution For Injection (SC)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
-
|
08 March 2022
|
28 July 2025
|
| View |
|
BR-1121
|
Trastuzumab
|
Herceptin
|
600 mg/ 5 mL (120 mg/ mL)
|
Solution For Injection (SC)
|
-
|
F. Hoffmann-La Roche AG
|
Switzerland
|
Regular Renewal (Compliance)
|
07 March 2022
|
29 September 2025
|
| View |
|
BR-1122
|
Rituximab
|
Mabthera
|
1400 mg/ 11.7 mL
|
Solution For Injection (SC)
|
-
|
F. Hoffman-La Roche AG
|
Switzerland
|
Regular Renewal (Compliance)
|
18 February 2022
|
29 September 2025
|
| View |
|
BR-1123
|
Obinutuzumab
|
Gazyva
|
1 g/40 mL (25mg/mL)
|
Concentrate For Solution For Infusion (IV)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
Initial (Variation)
|
12 August 2022
|
12 August 2027
|
| View |
BR-1125_PI_01.pdf
|
BR-1125
|
Quadrivalent Seasonal Influenza Vaccine (Split Virion,
Inactivated) Southern Hemisphere 2024 Strain.
|
Fluarix Tetra
|
Each dose (0.5 mL) contains the following influenza strains*:
A/Victoria/4897/2022 (H1N1)pdm09-like strain
(A/Victoria/4897/2022, IVR-238)
A/Thailand/8/2022 (H3N2)-like strain
(A/Thailand/8/2022, IVR-237)
B/Austria/1359417/2021-like strain
(B/Austria/1359417/2021, BVR-26)
B/Phuket/3073/2013-like strain
(B/Phuket/3073/2013, wild type) [Yamagata lineage] *Propagated in embryonated chicken eggs
**Haemagglutinin
15 μg of HA**
15 μg of HA**
15 μg of HA**
15 μg of HA**
|
Suspension for Injection (IM)
|
Vaccines
|
GlaxoSmithKline Biologicals NL Der SmithKline
|
Germany
|
Monitored Release (Strain Clearance)
|
19 February 2024
|
19 February 2025
|
| View |
|
BR-1126
|
Secukinumab
|
Cosentyx
|
150 mg/mL
|
Solution For Injection (SC)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG
|
Switzerland
|
Initial (from Monitored Release)
|
12 April 2022
|
06 January 2026
|
| View |
|
BR-1127
|
Secukinumab
|
Scapho
|
150 mg
|
Powder For Solution For Injection (SC)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
|
Switzerland
|
Initial (from Monitored Release)
|
07 April 2022
|
14 January 2026
|
| View |
BR-1130_PI_01.pdf
|
BR-1130
|
Secukinumab
|
Scapho
|
150 mg/mL
|
Solution For Injection (Sc)
|
-
|
Novartis Pharma Stein AG, Pharmaceutical
|
Switzerland
|
Initial (from Monitored Release)
|
11 April 2022
|
06 January 2026
|
| View |
|
BR-1133
|
Pneumococcal Conjugate Vaccine, 13-Valent
(adsorbed) [See formulation on reverse side]
|
Prevenar 13
|
0.5 mL
|
Suspension For Injection (IM)
|
-
|
Pfizer Ireland Pharmaceuticals
|
Ireland
|
-
|
10 September 2021
|
21 January 2026
|
| View |
|
BR-1135
|
Chorionic Gonadotrophin
|
Chorapur
|
5000 IU
|
Powder for Injection (IM)
|
-
|
Ferring GmbH
|
Germany
|
-
|
08 March 2021
|
09 February 2026
|
| View |
|
BR-1138
|
Pembrolizumab
|
Keytruda
|
100mg/4mL (25mg/mL
|
Solution For Injection (IV Infusion)
|
Antineoplastic
|
MSD International GmbH T/A MSD Ireland (Carlow)
|
Ireland
|
Initial
|
06 July 2021
|
17 February 2026
|
| View |
|
BR-1141
|
Rituximab
|
Mabthera
|
10 mg/ mL
|
Concentrate For Solution For Infusion (IV)
|
-
|
Roche Diagnostic GmbH
|
Germany
|
-
|
08 March 2021
|
24 November 2025
|
| View |
|
BR-1148
|
Combined Diphtheria, Tetanus, Acellular Pertussis Vaccine, Adsorbed
|
Boostrix
|
Formulation: 1 dose (0.5 mL) contains:
Diphtheria toxoid*-Not less than 2 IU (2.5Lf) Tetanus toxoid*-Not less than 20 IU (5Lf) Pertussis toxoid (PT)*-8mcg Filamentous Hemagglutinin (FHA)*-8mcg Pertactin-2.5mcg *adsorbed on Aluminum hydroxide, hydrated (Al(OH)3)-300 mcg Al3 and Aluminum phosphate (AlPO4)-200 mcg A13+
|
Suspension For Injection (I.M.)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
Renewal
|
27 April 2021
|
03 June 2026
|